• 1
    Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 36176.
  • 2
    Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004; 93: 117782.
  • 3
    Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998; 339: 103642.
  • 4
    Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989; 321: 41924.
  • 5
    Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 14918.
  • 6
    Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl. Cancer Inst. 2000; 92: 17319.
  • 7
    Aprikian AG, Fleshner N, Langleben A et al. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. Can. J. Urol. 2000; 10: 198694.
  • 8
    Fowler JE Jr, Pandey P, Seaver LE et al. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J. Urol. 1995; 154: 44853.
  • 9
    Stewart AJ, Scher HI, Chen MH et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J. Clin. Oncol. 2005; 23: 655660.
  • 10
    Janoff DM, Peterson C, Mongoue-Tchokote S et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int. 2005; 96: 5037.
  • 11
    Kwak C, Jeong SJ, Park MS et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J. Urol. 2002; 168: 9951000.
  • 12
    Fujii Y, Kawakami S, Masuda H et al. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int. 2006; 97: 11849.
  • 13
    May M, Gunia S, Helke C et al. Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model? Int. J. Biol. Markers 2005; 20: 11218.
  • 14
    Blasko JC, Grimm PD, Sylvester JE et al. Palladium-103 brachytherapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2000; 46: 83950.
  • 15
    Kakinuma H, Sasaki R, Sato K et al. Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma. Nippon Hinyokika Gakkai Zasshi 1996; 87: 9971003.